Abstract
Background: Upifitamab rilsodotin (UpRi; XMT-1536) is an investigational first-in-class antibody drug conjugate (ADC) targeting NaPi2b, a sodium-dependent phosphate transport protein broadly expressed in solid tumors and in approximately two-thirds of high-grade serous ovarian cancer (HGSOC) patients, with limited expression in normal tissue. Efficacy and safety data from a Phase 1b single-agent trial of UpRi in HGSOC was presented earlier this year (Richardson et al, SGO 2022). Archival tumor tissue and/or fresh biopsy (if medically feasible) were collected in this Ph 1 trial (NCT03319628) to compare the gene expression levels of NaPi2b and other genes of interest in archival vs fresh tumor samples in patients with platinum-resistant ovarian cancer.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
